来凯医药-B
港股通 官网
( 02105.hk)
市盈率-17.54市净率3.41股息率0%上市时间2023-06-29股价9.96港币涨跌幅0.50%成交金额2,750.05万港币换手率0.61%市值44.75亿港币H股市值44.75亿港币总股本4.49亿H股本4.49亿每手股数500上市至今年化投资收益率-13.22%港股通持仓占H股比例6.86% (3.26亿港币2026-06-03) 累计做空占H股比例1.85% (9,639.20万港币2026-05-29)
所属三级行业生物技术 (恒生) 市盈率97.58市净率3.79股息率0.44%恒生:医疗保健业药品及生物科技生物技术
备注 (2): 双击编辑备注
发表讨论

来凯医药-B(02105) - 历史董事名单

# 姓名职衔职位委任日期辞任日期
1鄒國強Independent Non Executive Director - A/F2023-06-16--
2LI MinIndependent Non Executive Director2023-06-16--
3YIN Xu DongIndependent Non Executive Director2023-06-16--
4GU Xiang Ju JustinExecutive Director2022-05-09--
5孫淵Non Executive Director2022-04-28--
6吉冬梅Non Executive Director2022-04-282023-09-29
7王國瑋Non Executive Director2019-07-01--
8XIE LingExecutive Director2018-05-11--
9LU Xiang Yang ChrisExecutive DirectorChairman2016-07-29--